Literature DB >> 21279708

Systemic inflammation and the dynamics of HDL cholesterol-associated residual cardiovascular risk.

Robert S Rosenson1.   

Abstract

Entities:  

Year:  2011        PMID： 21279708     DOI： 10.1007/s11883-011-0167-2

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  13 in total

1.  Functional assessment of HDL: Moving beyond static measures for risk assessment.

Authors:  Robert S Rosenson
Journal:  Cardiovasc Drugs Ther       Date:  2010-02       Impact factor: 3.727

2.  Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).

Authors: 
Journal:  Circulation       Date:  1998-04-21       Impact factor: 29.690

3.  Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.

Authors:  Robert S Rosenson
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

4.  HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.

Authors:  Paul M Ridker; Jacques Genest; S Matthijs Boekholdt; Peter Libby; Antonio M Gotto; Børge G Nordestgaard; Samia Mora; Jean G MacFadyen; Robert J Glynn; John J P Kastelein
Journal:  Lancet       Date:  2010-07-23       Impact factor: 79.321

5.  Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

Authors:  A M Gotto; E Whitney; E A Stein; D R Shapiro; M Clearfield; S Weis; J Y Jou; A Langendörfer; P A Beere; D J Watson; J R Downs; J S de Cani
Journal:  Circulation       Date:  2000-02-08       Impact factor: 29.690

Review 6.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.

Authors:  Jean-Charles Fruchart; Frank M Sacks; Michel P Hermans; Gerd Assmann; W Virgil Brown; Richard Ceska; M John Chapman; Paul M Dodson; Paola Fioretto; Henry N Ginsberg; Takashi Kadowaki; Jean-Marc Lablanche; Nikolaus Marx; Jorge Plutzky; Zeljko Reiner; Robert S Rosenson; Bart Staels; Jane K Stock; Rody Sy; Christoph Wanner; Alberto Zambon; Paul Zimmet
Journal:  Diab Vasc Dis Res       Date:  2008-11       Impact factor: 3.291

7.  Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.

Authors:  James D Otvos; Dorothea Collins; David S Freedman; Irina Shalaurova; Ernst J Schaefer; Judith R McNamara; Hanna E Bloomfield; Sander J Robins
Journal:  Circulation       Date:  2006-03-13       Impact factor: 29.690

8.  A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction.

Authors:  John D Seeger; Alexander M Walker; Paige L Williams; Gordon M Saperia; Frank M Sacks
Journal:  Am J Cardiol       Date:  2003-12-15       Impact factor: 2.778

9.  Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.

Authors:  Kausik K Ray; Christopher P Cannon; Richard Cairns; David A Morrow; Paul M Ridker; Eugene Braunwald
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-01-02       Impact factor: 8.311

10.  Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.

Authors:  Robert S Rosenson; James D Otvos; Judith Hsia
Journal:  Diabetes Care       Date:  2009-03-05       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.